RSV prevention tools somewhat cost-effective, studies show
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal respiratory syncytial virus (RSV) vaccination and the monoclonal antibody nirsevimab are likely cost effective in certain situations for RSV. These findings, both published today in Pediatrics, were presented to the CDC’s Advisory Committee on Immunization Practices (ACIP) and were instrumental in the recommendation of
